Overview
Registration
Agenda
Faculty
View Archive

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Celgene Corporation; Incyte Corporation; and PharmaEssentia USA.

2nd Annual Virtual Tumor Board®: Diagnosis and Management of Polycythemia Vera and Myelofibrosis

2nd Annual Virtual Tumor Board®: Diagnosis and Management of Polycythemia Vera and Myelofibrosis


Wednesday, May 20, 2020

Program: 8:00 p.m.- 9:30 p.m.

2nd Annual Virtual Tumor Board®: Diagnosis and Management of Polycythemia Vera and Myelofibrosis: Program Overview

This live video webcast will explore current trends in prognostic scoring, molecular diagnostics, and appropriate guideline-based management of myeloproliferative neoplasms (MPNs), as well as current and emerging therapeutic strategies of an array of agents including JAK inhibitors and interferons. By applying evidence in real-world case scenarios, this program contextualizes that evidence to ensure that practitioners are up-to-date with the evolving treatment landscape of polycythemia vera (PV) and myelofibrosis (MF), including current clinical trial findings, evolving treatment paradigms, and the mechanistic rationale for novel therapeutic approaches in the context of MPN pathophysiology. The program is designed to aid physicians in assessing the wealth of emerging data in treating MPNs, choosing appropriate treatment based upon patient and tumor characteristics, and applying novel management strategies to their practices to improve the care of patients.

Hot Topics

  • The progressing utility of interferons
  • High-risk mutations and their impact for treatment decision making
  • Novel JAK inhibitors on the horizon
  • Double and triple therapy combinations in clinical development

Acknowledgement of Commercial Support

This activity is supported by educational grants from Celgene Corporation; Incyte Corporation; and PharmaEssentia USA.

Target Audience: HCPs Who Treat Myeloproliferative Neoplasms

This educational activity is directed toward hematologists, medical oncologists, and fellows involved in the treatment and management of patients with MPNs. Nurse practitioners (NPs), nurses, physician assistants (PAs), pharmacists, researchers, and other healthcare professionals interested in the treatment of MPNs may also participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Outline the latest discoveries in the biology of MF and PV and their potential impact on clinical decision making.
  • Explain current clinical management strategies for patients with MF and PV.
  • Summarize ongoing clinical trials and their potential impact on the treatment landscape of MF and PV.
  • Implement multidisciplinary strategies to effectively counsel patients with MF and PV concerning treatment-related toxicities and management of disease-related symptoms.

Program Chair

Ronald Hoffman
Ronald Hoffman, MD
Albert A. and Vera G. List Professor of Medicine
Director, Myeloproliferative Disorders Research Program
Tisch Cancer Institute
Icahn School of Medicine
New York, NY




Register

You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information


Registration Information


Professional Information


Specialties*

Submit
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
31
Filter By